UNAUDITED CONDENSED FINANCIAL STATEMENTS
FOR THE 3-MONTH AND 9-MONTH PERIODS ENDED SEPTEMBER 30, 2026 AND SEPTEMBER 30, 2025KP Tissue Inc.
2 Prologis Blvd., Suite 500, Mississauga, Ontario L5W 0G8 https://www.kptissueinc.com
Unaudited Condensed Statements of Financial Position(tabular amounts are in thousands of Canadian dollars)
September 30, 2026 Note $ | December 31, 2025 $ | |
Assets Current assets Dividends receivable | 2,107 | 1,803 |
Non-current assets Investment in associate 5 | 2,107 76,293 | 1,803 69,799 |
Total assets | 78,400 | 71,602 |
Liabilities Current liabilities Dividends payable 6 | 2,107 | 1,803 |
Total liabilities Equity Common shares 6 Contributed surplus Deficit Accumulated other comprehensive income | 2,107 23,194 144,819 (109,511) 17,791 | 1,803 23,001 144,819 (114,985) 16,964 |
Total equity | 76,293 | 69,799 |
Total liabilities and equity | 78,400 | 71,602 |
(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)
Note | 3-month period ended September 30, 2026 $ | 3-month period ended | 9-month period ended | 9-month period ended |
September 30, 2025 September 30, 2026 $ $ | September 30, 2025 $ | |||
Share of income | 3,310 | 1,700 | 8,359 | 6,372 |
Depreciation of fair value increments | (269) | (264) | (808) | (827) |
Equity income | 3,041 | 1,436 | 7,551 | 5,545 |
Dilution gain | 59 | 114 | 171 | 323 |
Net income | 3,100 | 1,550 | 7,722 | 5,868 |
Other comprehensive income (loss) net of income tax expense (recovery) 6 Items that will not be reclassified to net income: Remeasurements of pensions Remeasurements of post-retirement benefits Items that may be subsequently reclassified to net income: Cumulative translation adjustment | 2,293 | 441 | 3,468 | 537 |
284 | 5 | 301 | 34 | |
(56) | 523 | 827 | (1,227) | |
Other comprehensive income (loss) | 2,521 | 969 | 4,596 | (656) |
Total comprehensive income | 5,621 | 2,519 | 12,318 | 5,212 |
Basic and diluted earnings per share | 0.31 | 0.15 | 0.77 | 0.59 |
Weighted average number of shares outstanding | 10,031,675 | 10,007,057 | 10,026,643 | 10,000,087 |
(tabular amounts are in thousands of Canadian dollars, except share amounts)
Note | # | Share capital $ | Contributed surplus Deficit $ $ | Accumulated other comprehensive income $ | Total equity $ | ||
As of January 1, 2026 | 10,015,366 | 23,001 | 144,819 | (114,985) | 16,964 | 69,799 | |
Issuance of common shares | 6 | 17,021 | 192 | - | - | - | 192 |
Dividends payable | 6 | - | - | - | (2,107) | - | (2,107) |
Dividends paid | - | - | - | (3,909) | - | (3,909) | |
Fair value adjustment | - | 1 | - | (1) | - | - | |
Remeasurement of pensions | - | - | - | 3,468 | - | 3,468 | |
Remeasurement of post-retirement benefits | - | - | - | 301 | - | 301 | |
Cumulative translation adjustment | - | - | - | - | 827 | 827 | |
Net income | - | - | - | 7,722 | - | 7,722 | |
As of September 30, 2026 | 10,032,387 | 23,194 | 144,819 | (109,511) | 17,791 | 76,293 | |
Share capital | Contributed surplus Deficit $ $ | Accumulated other comprehensive income $ | Total equity $ | ||||
Note | # | $ | |||||
As of January 1, 2025 | 9,987,547 | 22,762 | 144,819 | (116,673) | 18,609 | 69,517 | |
Issuance of common shares | 6 | 20,612 | 170 | - | - | - | 170 |
Dividends payable | 6 | - | - | - | (1,801) | - | (1,801) |
Dividends paid | - | - | - | (3,598) | - | (3,598) | |
Fair value adjustment | - | 2 | - | (2) | - | - | |
Remeasurement of pensions | - | - | - | 537 | - | 537 | |
Remeasurement of post-retirement benefits | - | - | - | 34 | - | 34 | |
Cumulative translation adjustment | - | - | - | - | (1,227) | (1,227) | |
Net income | - | - | - | 5,868 | - | 5,868 | |
As of September 30, 2025 | 10,008,159 | 22,934 | 144,819 | (115,635) | 17,382 | 69,500 | |
(tabular amounts are in thousands of Canadian dollars)
Note | 9-month period ended September 30, 2026 $ | 9-month period ended September 30, 2025 $ | |
Cash flows from (used in) operating activities | |||
Net income | 7,722 | 5,868 | |
Items not affecting cash | |||
Equity income | (7,551) | (5,545) | |
Dilution gain | (171) | (323) | |
Total items not affecting cash | (7,722) | (5,868) | |
Net cash from operating activities | - | - | |
Cash flows from (used in) investing activities Dividends received, net | 6 | 5,522 | 5,229 |
Net cash from investing activities | 5,522 | 5,229 | |
Cash flows from (used in) financing activities Dividends paid, net | 6 | (5,522) | (5,229) |
Net cash used in financing activities | (5,522) | (5,229) | |
Increase in cash and cash equivalents during the period | - | - | |
Cash and cash equivalents - Beginning of period | - | - | |
Cash and cash equivalents - End of period | - | - | |
(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)
- GENERAL INFORMATION
KP Tissue Inc. (KPT or the Corporation) was incorporated by articles of incorporation under the Canadian Business Corporations Act on October 1, 2012. As of September 30, 2026, the Corporation held a 12.0% interest in Kruger Products Inc. (Kruger Products) (December 31, 2025 - 12.1%).
Kruger Products' principal business is to produce, distribute, market and sell a wide range of disposable tissue products, including bathroom tissue, facial tissue, paper towels and napkins for both the consumer and away-from-home markets in North America. The Corporation's headquarters are located in Mississauga, Ontario, Canada.
- BASIS OF PRESENTATION
These unaudited condensed financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards) applicable to the preparation of interim financial statements, including International Accounting Standards (IAS) 34 - Interim Financial Reporting as issued by the International Accounting Standards Board (IASB), and with interpretations of the International Financial Reporting Committee which the Canadian Accounting Standards Board has approved for incorporation into Part 1 of the CPA Canada Handbook - Accounting. These unaudited condensed financial statements should be read in conjunction with the annual audited financial statements of the Corporation for the year ended December 31, 2025.
These unaudited condensed financial statements were approved by the board of directors on November 10, 2026.
- SUMMARY OF MATERIAL ACCOUNTING POLICIES
The material accounting policies used in the preparation of these unaudited condensed financial statements were disclosed in the annual audited financial statements of the Corporation for the year ended December 31, 2025 and have been applied to all periods presented.
Accounting standard implemented effective January 1, 2026Amendments to IFRS 9 and IFRS 7 - Amendments to the Classification and Measurement of Financial Instruments
On May 30, 2024, the IASB issued amendments to IFRS Accounting Standards 9 and IFRS Accounting Standards 7 aimed at improving the classification and measurement of financial instruments. The recent amendments simplify financial reporting by allowing earlier recognition of liabilities settled via electronic payments, clarifying the assessment of cash flows for basic lending arrangements, and refining definitions for non-recourse features and linked instruments. The amendments also introduce more detailed disclosure requirements for fair value changes in equity instruments and mandate reporting of terms that could affect cash flow timings or amounts. The amendments are effective for periods beginning on or after January 1, 2026 and adoption of these amendments did not have a material effect on the Corporation's condensed interim financial statements. For financial liabilities settled in cash using an electronic payment system, the election was applied to deem these financial liabilities to be discharged before the settlement date. The amendments were applied retrospectively, with no restatement of comparative information, in accordance with transition requirements on initial application of IFRS 9.
(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)
Accounting standard issued but not yet implemented:IFRS 18, Presentation and Disclosure in Financial Statements
In April 2024, the IASB issued IFRS 18 to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS 1, impacts the presentation of primary financial statements and notes, mainly the income statement where companies will be required to present separate categories of income and expense for operating, investing, and financing activities with prescribed subtotals for each new category. IFRS 18 will require management-defined performance measures to be explained and included in a separate note within the unaudited condensed financial statements. The mandatory effective date would be for annual reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application. The Corporation has substantially completed its assessment of IFRS 18 and does not expect the adoption of the standard to have a material impact on its unaudited condensed statement of income. The adoption of IFRS 18 is not expected to impact the Corporation's reported financial results.
- CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS
The preparation of these unaudited condensed financial statements in conformity with IFRS Accounting Standards requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities in the unaudited condensed financial statements and the disclosure of contingencies at the dates of the unaudited condensed statement of financial position, and the reported amounts of revenues and expenses during the reporting period. On a regular basis and with the information available, management reviews its estimates and judgments, including those related to fair value and the basis of accounting. Actual results could differ from those estimates. When adjustments become necessary, they are reported in earnings in the period in which they occur.
The estimates and judgement applied by management that most significantly affect the unaudited condensed financial statements are the same as the ones that applied to the annual audited financial statements for the year ended December 31, 2025.
- INVESTMENT IN ASSOCIATE
Changes in the carrying amount of the investment were as follows:
9-month period ended
September 30, 2026
9-month period ended
September 30, 2025
$
$
Opening balance
69,799
69,517
Increase in investment
192
170
Share of income
8,359
6,372
Depreciation of fair value increments
(808)
(827)
Share of other comprehensive income (loss)
4,596
(656)
Dilution gain
171
323
Dividends
(6,016)
(5,399)
Closing balance
76,293
69,500
(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)
The following summarizes financial information about the assets, liabilities, revenue and net income of Kruger Products, in which the Corporation holds a 12.0% interest as of September 30, 2026. The financial information was derived from the unaudited condensed financial statements of Kruger Products for the 3-month and 9-month periods ended September 30, 2026. The assets and liabilities disclosed include the fair value adjustments made to the carrying amount of the assets and liabilities of the associate on its acquisition.
September 30, 2026
Kruger Products Fair value
basis of accounting increment
$ $
KPT
basis of accounting
$
Current assets
724,830
-
724,830
Non-current assets
2,002,388
285,267
2,287,655
Liabilities
1,942,563
-
1,942,563
Net assets
784,655
3-month period ended
9-month period ended
September 30, 2026
September 30, 2026
$
$
Revenue
Net income attributable to Kruger Products Other comprehensive income
589,655
27,708
21,188
1,685,193
69,637
37,740
Total comprehensive income attributable to Kruger Products
48,896
107,377
December 31, 2025
Kruger Products Fair value
basis of accounting increment
$ $
KPT
basis of accounting
$
Current assets
678,083
-
678,083
Non-current assets
1,930,621
291,198
2,221,819
Liabilities
1,902,159
-
1,902,159
Net assets
706,545
3-month period ended
9-month period ended
September 30, 2025
September 30, 2025
$
$
Revenue 561,145
Net income attributable to Kruger Products 14,546
Other comprehensive income (loss) 7,603
1,643,335
52,088
(3,227)
Total comprehensive income attributable to Kruger Products 22,149
48,861
(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)
The following shows the reconciliation of KPT's portion of Kruger Products equity to the investment recorded in KPT:
September 30, 2026
December 31, 2025
$
$
Kruger Products consolidated equity
784,655
706,545
Add back: Inception value of common shares
118,562
118,562
Less: Equity pertaining to Kruger Inc. and KPGP
(746,287)
(675,242)
Equity pertaining to KPT
156,930
149,865
Investment in associate recorded in KPT
76,293
69,799
Reconciling difference
80,637
80,066
Reconciling items since inception:
Equity issuance costs
(11,110)
(11,110)
Depreciation of fair value increments
63,361
62,553
Currency translation adjustment in fair value increments
(2,895)
(2,829)
Tax Distribution
9,181
9,181
Gain on exercise of overallotment option
(375)
(375)
Dilution gain
(5,525)
(5,354)
Impairment in investment in associate
28,000
28,000
-
-
With respect to KPT's investment in Kruger Products, the liability of KPT for the debts, liabilities and other obligations of Kruger Products is limited to KPT's capital contribution to Kruger Products.
- DIVIDENDS
During the 9-month periods ended September 30, 2026 and September 30, 2025, the Corporation paid quarterly dividends to shareholders. Pursuant to the Corporation Dividend Reinvestment Plan (DRIP), a portion of the dividend was reinvested by the shareholders, resulting in the Corporation issuing common shares. The proceeds were used to acquire additional shares of Kruger Products. The amount per share, dividends paid, additional common shares issued at the share price, and the gross proceeds were as follows:
Dividend Payment Date
Amount per share Dividends paid
$ $
Issuance of Share price common shares
$ #
2026
Gross proceeds
$
January 15, 2026
0.18
1,803
10.21
6,971
71
April 15, 2026
0.18
1,804
11.09
5,374
60
July 15, 2026
0.21
2,107
13.06
4,676
61
5,714
17,021
192
Dividend Payment Date
Amount per share Dividends paid
$ $
Issuance of Share price common shares
$ #
2025
Gross proceeds
$
January 15, 2025
0.18
1,798
8.06
6,656
54
April 15, 2025
0.18
1,799
7.86
6,713
54
July 15, 2025
0.18
1,802
8.87
7,243
62
5,399
20,612
170
(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)
Subsequent to September 30, 2026, on October 15, 2026, the Corporation paid a dividend of $2.1 million to shareholders at $0.21 per common share. Pursuant to the Corporation DRIP, a portion of the dividend was reinvested by the shareholders, resulting in the Corporation issuing 5,582 common shares at a price of $11.80.
Subsequent to September 30, 2026, the Corporation declared a dividend of $2.1 million, payable on January 15, 2027 at $0.21 per common share.
As a result of the DRIP and Kruger Inc.'s reinvestment of its dividends from Kruger Products in common shares of Kruger Products, a dilution gain of $0.2 million was recorded during the 9-month period ended September 30, 2026 (9-month period ended September 30, 2025 - $0.3 million).
- ECONOMIC DEPENDENCE
The Corporation was created to acquire, and its business is limited to holding, a limited equity interest in Kruger Products, which is accounted for as an investment in an associate using the equity method of accounting. As such, the Corporation is economically dependent on Kruger Products and exposed to all the risks associated with the business of Kruger Products, including, but not limited to, liquidity risk.
